| The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria International Team for the Revision of the International Criteria for Behçet ... Journal of the european Academy of Dermatology and Venereology 28 (3), 338-347, 2014 | 1071 | 2014 |
| CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer EM Bange, NA Han, P Wileyto, JY Kim, S Gouma, J Robinson, ... Nature medicine 27 (7), 1280-1289, 2021 | 468 | 2021 |
| PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's … AJ Moskowitz, H Schöder, J Yahalom, SJ McCall, SY Fox, J Gerecitano, ... The lancet oncology 16 (3), 284-292, 2015 | 305 | 2015 |
| Imaging for staging and response assessment in lymphoma SA Johnson, A Kumar, MJ Matasar, H Schöder, J Rademaker Radiology 276 (2), 323-338, 2015 | 206 | 2015 |
| Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups CL Batlevi, F Sha, A Alperovich, A Ni, K Smith, Z Ying, JD Soumerai, ... Blood cancer journal 10 (7), 74, 2020 | 181 | 2020 |
| Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma AJ Moskowitz, G Shah, H Schöder, N Ganesan, E Drill, H Hancock, ... Journal of Clinical Oncology 39 (28), 3109-3117, 2021 | 158 | 2021 |
| Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma AJ Moskowitz, H Schöder, S Gavane, KL Thoren, M Fleisher, J Yahalom, ... Blood, The Journal of the American Society of Hematology 130 (20), 2196-2203, 2017 | 143 | 2017 |
| Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse A Kumar, F Sha, A Toure, A Dogan, A Ni, CL Batlevi, MLM Palomba, ... Blood Cancer Journal 9 (6), 50, 2019 | 115 | 2019 |
| Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies D Sermer, C Batlevi, ML Palomba, G Shah, RJ Lin, MA Perales, M Scordo, ... Blood advances 4 (19), 4669-4678, 2020 | 107 | 2020 |
| Lack of benefit of central nervous system prophylaxis for diffuse large B‐cell lymphoma in the rituximab era: findings from a large national database A Kumar, A Vanderplas, AS LaCasce, MA Rodriguez, AL Crosby, ... Cancer 118 (11), 2944-2951, 2012 | 107 | 2012 |
| Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small … JD Soumerai, AR Mato, A Dogan, VE Seshan, E Joffe, K Flaherty, J Carter, ... The Lancet Haematology 8 (12), e879-e890, 2021 | 105 | 2021 |
| Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms NE Lewis, K Petrova-Drus, S Huet, ZD Epstein-Peterson, Q Gao, ... Blood advances 4 (10), 2261-2271, 2020 | 91 | 2020 |
| A multicenter study of depression among emergency department patients A Kumar, S Clark, ED Boudreaux, CA Camargo Jr Academic emergency medicine 11 (12), 1284-1289, 2004 | 88 | 2004 |
| Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma A Kumar, C Casulo, J Yahalom, H Schöder, PM Barr, P Caron, A Chiu, ... Blood, The Journal of the American Society of Hematology 128 (11), 1458-1464, 2016 | 81 | 2016 |
| A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL CS Sauter, MJ Matasar, H Schoder, SM Devlin, P Drullinsky, J Gerecitano, ... Blood, The Journal of the American Society of Hematology 131 (16), 1805-1808, 2018 | 79 | 2018 |
| Prevalence, prognosis, and implications of isolated minor nonspecific ST-segment and T-wave abnormalities in older adults: Cardiovascular Health Study A Kumar, RJ Prineas, AM Arnold, BM Psaty, CD Furberg, J Robbins, ... Circulation 118 (25), 2790-2796, 2008 | 73 | 2008 |
| Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma ME Mayerhoefer, CC Riedl, A Kumar, P Gibbs, M Weber, I Tal, J Schilksy, ... European Journal of Nuclear Medicine and Molecular Imaging 46, 2760-2769, 2019 | 70 | 2019 |
| Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes A Kumar, IA Burger, Z Zhang, EN Drill, JC Migliacci, A Ng, A LaCasce, ... Haematologica 101 (10), 1237, 2016 | 66 | 2016 |
| Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma ML Wang, W Jurczak, PL Zinzani, TA Eyre, CY Cheah, CS Ujjani, Y Koh, ... Journal of Clinical Oncology 41 (24), 3988-3997, 2023 | 61 | 2023 |
| Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era S Bobillo, E Joffe, JA Lavery, D Sermer, P Ghione, A Noy, PC Caron, ... Blood, The Journal of the American Society of Hematology 137 (1), 39-48, 2021 | 61 | 2021 |